{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T11:55:16Z","timestamp":1772711716762,"version":"3.50.1"},"reference-count":22,"publisher":"Informa UK Limited","issue":"12","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"BeOne Medicines"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2025,12,2]]},"DOI":"10.1080\/03007995.2026.2620691","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T12:28:00Z","timestamp":1769776080000},"page":"2357-2367","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage small-cell lung cancer: patient-reported outcomes in the RATIONALE-312 trial"],"prefix":"10.1080","volume":"41","author":[{"given":"Ying","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Jilin Cancer Hospital","place":["Changchun, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tai","family":"Qin","sequence":"additional","affiliation":[{"name":"BeOne Medicines, Ltd","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenqi","family":"Chen","sequence":"additional","affiliation":[{"name":"BeOne Medicines, Ltd","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick","family":"B. Barnes","sequence":"additional","affiliation":[{"name":"BeOne Medicines, Ltd","place":["San Carlos, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisoo","family":"Barnes","sequence":"additional","affiliation":[{"name":"BeOne Medicines, Ltd","place":["San Carlos, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113581"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00235-0"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00339"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.15310"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2022.2078101"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2023.100572"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000583"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100501"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6361"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.03.008"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(94)90535-5"},{"key":"e_1_3_6_14_1","unstructured":"Administration TUFaD. Core patient-reported outcomes in cancer clinical trials guidance for industry: the US Food and Drug Administration; 2024 [cited 2025 Apr 1]. Rockville MD: U.S. Food and Drug. Available from: https:\/\/www.fda.gov\/media\/149994\/download"},{"key":"e_1_3_6_15_1","unstructured":"Administration TUFaD. Patient-focused drug development guidance: methods to identify what is important to patients and select develop or modify fit-for-purpose clinical outcome assessments. The US Food and Drug Administration; 2018 [cited 2025 Apr 1]. Rockville MD: U.S. Food and Drug. Available from: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/patient-focused-drug-development-guidance-methods-identify-what-important-patients-and-select"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.139"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.2015.1115348"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00273.x"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00439229"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-010-1016-5"},{"key":"e_1_3_6_21_1","unstructured":"NIH. Small cell lung cancer treatment (PDQ\u00ae)\u2013patient version: National Cancer Institute; 2025 [cited 2025 Apr 1]. Washington DC: U.S. Department of Health and Human Services. Available from: https:\/\/www.cancer.gov\/types\/lung\/patient\/small-cell-lung-treatment-pdq"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.021"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.09.003"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2026.2620691","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T10:56:47Z","timestamp":1772708207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03007995.2026.2620691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,2]]}},"alternative-id":["10.1080\/03007995.2026.2620691"],"URL":"https:\/\/doi.org\/10.1080\/03007995.2026.2620691","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-11-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}